Related Experiment Videos
Hyperekplexia: abnormal startle response due to glycine receptor mutations
1Department of Psychological Medicine, University of Wales College of Medicine, Cardiff.
The British Journal of Psychiatry : the Journal of Mental Science
|February 1, 1997
Summary
Hyperekplexia, a rare neurological disorder, is caused by mutations in the glycine receptor gene (GLRA1). Treatment involves benzodiazepines like clonazepam, and genetic analysis aids diagnosis and counseling.
Area of Science:
- Neuroscience
- Genetics
- Clinical Medicine
Background:
- Hyperekplexia is a rare disorder characterized by exaggerated startle responses and neonatal hypertonia.
- Mutations in the alpha 1 subunit of the glycine receptor (GLRA1) are a common cause.
Purpose of the Study:
- To review the clinical features, management, and genetic underpinnings of hyperekplexia.
- To highlight the significance of GLRA1 mutations in this condition.
Main Methods:
- Review of clinical features and management strategies for hyperekplexia.
- Analysis of recent genetic studies, including mutation analysis of GLRA1.
- Examination of findings in mouse models with startle phenotypes.
Main Results:
- Diagnosis is achievable with awareness of the syndrome.
- Clonazepam is the primary treatment, offering significant but incomplete symptom reduction.
- Both dominant and recessive GLRA1 mutations are identified; other cases may involve the glycine receptor beta subunit.
Conclusions:
- Hyperekplexia represents the first identified human disease linked to neurotransmitter gene mutations.
- The discovery of both dominant and recessive inheritance patterns in GLRA1 is significant for understanding channelopathies.
- GLRA1 mutation analysis is valuable for genetic counseling and diagnosing neonatal hypertonia.